Why it matters: The partnership between Enthea and two companies, Skylight Psychedelics and Innerwell, allows for nationwide availability of ketamine-assisted therapy as a health benefit. This expands access to psychedelic therapy for workplace mental health challenges.
What they are saying: Enthea’s CEO states that nationwide availability is a pivotal moment in their mission to help employers with mental health challenges. The co-founder of Skylight Psychedelics expresses excitement about expanding access to cutting-edge treatments, including ketamine-assisted therapy.
The big picture: Ketamine is the only drug with known psychedelic effects approved by the FDA for mental health treatments. Offering ketamine therapy as a health benefit allows eligible employees to access it without the high costs associated with psychedelic assisted therapy. Enthea aims to increase the number of eligible individuals to 200,000 by the end of next year.
What to watch: The expansion of ketamine-assisted therapy as a health benefit could have significant implications for workplace mental health and the adoption of emerging psychedelic medicine modalities. It will be important to monitor the impact of this partnership on employee well-being and treatment efficacy.
My take: The partnership between Enthea, Skylight Psychedelics, and Innerwell is a positive step towards increasing access to psychedelic therapy for mental health challenges in the workplace. By offering ketamine-assisted therapy as a health benefit, employers can provide their employees with innovative treatments that have shown promising results. This expansion has the potential to positively impact the mental health of employees and contribute to the growing acceptance and adoption of psychedelic-assisted therapies.
